BeyondSpring (BYSI) Other Non-Current Assets (2016 - 2026)
BeyondSpring's (BYSI) quarterly Other Non-Current Assets came in at $4.3 million in Q2 2026, down 72.86% year-over-year from $15.7 million in Q2 2025, and down 19.27% quarter-over-quarter from $5.3 million in Q1 2026.
Analysis
BeyondSpring (BYSI) Other Non-Current Assets (2016 - 2026) Analysis & Trends
BeyondSpring has disclosed Other Non-Current Assets across 11 years of filings, most recently posting $4.3 million for Q2 2026.
- In Q2 2026, Other Non-Current Assets fell 72.86% year-over-year to $4.3 million; the TTM figure through Jun 2026 stood at $4.3 million (down 72.86% YoY), while the FY2025 annual figure was $8.0 million, down 68.35% from the prior year.
- Other Non-Current Assets came in at $4.3 million for Q2 2026 at BeyondSpring, down from $5.3 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $25.3 million in Q4 2024 to a low of $114000.0 in Q2 2022.
- Average Other Non-Current Assets over 5 years is $8.3 million, with a median of $5.3 million recorded in 2023.
- Year-over-year, Other Non-Current Assets sank 91.83% in 2022 and surged 3462.81% in 2025.
- Over 5 years, Other Non-Current Assets stood at $347000.0 in 2022, then surged by 1404.03% to $5.2 million in 2023, then soared by 385.67% to $25.3 million in 2024, then sank by 68.35% to $8.0 million in 2025, then tumbled by 46.84% to $4.3 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $4.3 million in Q2 2026, $5.3 million in Q1 2026, and $8.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 9.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 5.50 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 42.45 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 86.76 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 239.50 Mn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - | 4.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.27 Mn |
| Mar 31, 2026 | 5.28 Mn |
| Dec 31, 2025 | 8.02 Mn |
| Sep 30, 2025 | 11.41 Mn |
| Jun 30, 2025 | 15.71 Mn |
| Mar 31, 2025 | 22.63 Mn |
| Dec 31, 2024 | 25.35 Mn |
| Jun 30, 2024 | 441,000.00 |
| Dec 31, 2023 | 5.22 Mn |
| Jun 30, 2023 | 341,000.00 |
| Dec 31, 2022 | 347,000.00 |
| Jun 30, 2022 | 114,000.00 |
| Dec 31, 2021 | 3.12 Mn |
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 1.40 Mn |
| Mar 31, 2021 | 1.30 Mn |
| Dec 31, 2020 | 1.28 Mn |
| Sep 30, 2020 | 1.18 Mn |
| Jun 30, 2020 | 1.09 Mn |
| Mar 31, 2020 | 941,000.00 |